Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma

Analytical and Quantitative Cytology and Histology

Volumn 32, Issue 1, 2010, Pages 39-44

  Compérat, Eva ^a   Egevad, Lars ^b,c   Camparo, Philippe ^d   Roupret, Morgan ^a   Vaessen, Christophe ^a   Valdman, Alexander ^e   Jonmarker, Sara ^e   Capron, Fréderique ^a   Cussenot, Olivier ^f   Charlotte, Fréderic ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Hôpital d'Instruction des Armées du Val du Grâce   (France)

^e KAROLINSKA INSTITUTE   (Sweden)

^f HÔPITAL TENON   (France)

Author keywords

CD8; Foxp3; Immune response; Prostate cancer; Treg cells

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL MATURATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

AGED; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 77951138914     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32 (Pubitemid 33070205)
2. Sakaguchi S: Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562
3. Kronenberg M, Rudensky A: Regulation of immunity by self-reactive T cells. Nature 2005;435:598-604
4. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S: Thymus and autoimmunity: Production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999;162:5317-5326 (Pubitemid 29307138)
5. Maloy KJ, Powrie F: Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816-822
6. Suciu-Foca N, Manavalan JS, Cortesini R: Generation and function of antigen-specific suppressor and regulatory T cells. Transpl Immunol 2003;11:235-244 (Pubitemid 37120543)
7. Akbar AN, Taams LS, Salmon M, Vukmanovic-Stejic M: The peripheral generation of CD4+ CD25+ regulatory T cells. Immunology 2003;109:319-325
8. Billerbeck E, Blum HE, Thimme R: Parallel expansion of human virus-specific FoxP3- effector memory and de novogenerated FoxP3+ regulatory CD8+ T cells upon antigen recognition in vitro. J Immunol 2007;179:1039-1048
9. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061 (Pubitemid 36222930)
10. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs: The development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336
11. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003;112:1437-1443 (Pubitemid 38057697)
12. Singh RP, La Cava A, Wong M, Ebling F, Hahn BH: CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol 2007;178:7649-7657 (Pubitemid 46898035)
13. Thompson C, Powrie F: Regulatory T cells. Curr Opin Pharmacol 2004;4:408-414
14. Ziegler SF: FOXP3: Of mice and men. Annu Rev Immunol 2006;24:209-226
15. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohasi S: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007;13:902-911 (Pubitemid 46340366)
16. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED: Tumor-infiltrating Foxp3-CD4+ CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075-2081
17. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, Grutzmann R, Pilarsky C, Ungefroren H, Saeger HD, Kloppel G, Kabelitz D, Kalthoff H: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007;67:8344-8350 (Pubitemid 47395173)
18. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH: Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 2007;177:353-358 (Pubitemid 44879486)
19. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761 (Pubitemid 34921025)
20. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457-2464 (Pubitemid 40490158)
21. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 2003;98:1089-1099 (Pubitemid 37022112)
22. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C, Piris MA: Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467-1473 (Pubitemid 40315228)
23. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C: The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326-8331 (Pubitemid 41746944)
24. Schreiber TH: The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors. Cancer Epidemiol Biomarkers Prev 2007;16:1931-1934
25. Siesling S, van Dijck JA, Visser O, Coebergh JW: Trends in incidence of and mortality from cancer in The Netherlands in the period 1989-1998. Eur J Cancer 2003;39:2521-2530
26. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P: CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-7405 (Pubitemid 44715110)
27. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M: Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005;35:66-75 (Pubitemid 40123853)
28. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V: Inflammation and chronic prostatic diseases: Evidence for a link? Eur Urol 2007;52:964-972
29. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor OA, Hu JJ, Ochoa AC: Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008;29:573-578 (Pubitemid 351404874)
30. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-269
31. De Marzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-1992
32. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG: Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis 2005;26:1170-1181 (Pubitemid 41417894)
33. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-3633 (Pubitemid 43121851)
34. Orentas RJ, Kohler ME, Johnson BD: Suppression of anticancer immunity by regulatory T cells: Back to the future. Semin Cancer Biol 2006;16:137-149
35. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H: Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Invest Drugs 2007;8:1002-1008
36. Zeiser R, Negrin RS: Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008;7:458-462 (Pubitemid 351366473)
37. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: WHO Classification of Tumors: Tumors of the Genitourinary and Male Genital Organs. Lyon, IARC Press, 2004
38. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242
39. Comperat E, Camparo P, Haus R, Chartier-Kastler E, Radenen B, Richard F, Capron F, Paradis V: Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: A study of 128 cases of non-invasive neoplasms. Virchows Arch 2007;450:419-424 (Pubitemid 46466396)
40. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, Toms C, Fox BC, Cerundolo V, Powrie F, Banham AH: Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005;35:1681-1691 (Pubitemid 40862316)
41. Betts GJ, Clarke SL, Richards HE, Godkin AJ, Gallimore AM: Regulating the immune response to tumours. Adv Drug Deliv Rev 2006;58:948-961
42. Degl'Innocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio MT, Hess-Michelini R, Doglioni C, Bellone M: Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res 2008;68:292-300 (Pubitemid 351380131)
43. Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, Thompson TC, Old LJ, Wang RF: CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947-6958
44. Filaci G, Fenoglio D, Fravega M, Ansaldo G, Borgonovo G, Traverso P, Villaggio B, Ferrera A, Kunkl A, Rizzi M, Ferrera F, Balestra P, Ghio M, Contini P, Setti M, Olive D, Azzarone B, Carmignani G, Ravetti JL, Torre G, Indiveri F: CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007;179:4323-4334
45. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E: Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-472 (Pubitemid 43166137)
46. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C: Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: Role of tumor-derived TGF-beta. J Immunol 2007;178:2883-2892
47. Jarnicki AG, Lysaght J, Todryk S, Mills KH: Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006;177:896-904 (Pubitemid 44036590)